Author Interviews, Biomarkers, Gastrointestinal Disease / 28.03.2020

MedicalResearch.com Interview with: Jean-Frederic Colombel MD The Henry D Janowitz Division of Gastroenterology Icahn School of Medicine at Mount Sina New York, NY 10029, USA MedicalResearch.com: What is the background for this study? Response: The goals of therapy in Crohn’s disease have shifted from mere control of symptoms also called clinical remission towards combination of clinical and endoscopic remission also called deep remission which is now considered as the new therapeutic “target”. However it has yet to be proven that targeting deep remission instead of clinical remission is able to stop the progression of Crohn’s disease towards bowel damage, complications and hospitalizations. This study is a post-hoc analysis of the CALM trial that was published in The Lancet in 2018 where newly diagnosed patients were randomized to escalate therapy based on symptoms only (control arm) or based on a combination of symptoms and two biomarkers namely C-reactive protein in blood and calprotectin in stools (tight control arm). (more…)
Author Interviews, COVID -19 Coronavirus, NEJM / 28.03.2020

MedicalResearch.com Interview with: Bin Cao, Yeming Wang, Guohui Fan, Lianghan Shang, Jiuyang Xu, DingyuZhang, Chen Wang on behalf of LOTUS-China Study Group China-Japan Friendship Hospital; Wuhan Jintinyan Hospital; Institute of Respiratory Medicine, Chinese Academy of Medical Science  MedicalResearch.com: What is the background for this study? Response: In the past two months, the outbreak of Coronavirus Disease 2019 (COVID-19) has been spreading rapidly across the world. Science and technology is the most powerful weapon for human to fight against diseases, especially in such a pandemic setting. Seeking for effective antiviral medication is the most critical and urgent among the many scientific tasks in the pandemic. At the most critical moment in the fight against COVID-19, Chinese clinical scientists have stepped forward under extremely difficult research conditions to carry out clinical trials in antiviral treatment including lopinavir–ritonavir and remdesivir, in a swift, decisive and effective manner. These trials have attracted worldwide attention. Recently, the Lopinavir–ritonavir Trial for suppression of SARS-CoV-2 in China (LOTUS-China) has been completed, which, with great clinical significance, can provide strong evidence for the treatment of COVID-19 both in China and around the world. (more…)
Author Interviews, COVID -19 Coronavirus, Lung Cancer / 27.03.2020

MedicalResearch.com Interview with: Dr. Amy C. Moore PhD Director of Science and Research GO2 Foundation for Lung Cancer MedicalResearch.com: What is the mission of the GO2 Foundation for Lung Cancer? Response: GO2 Foundation for Lung Cancer’s mission is to transform survivorship by  saving, extending, and improving the lives of those vulnerable, at risk, and diagnosed with lung cancer. (more…)
Author Interviews, COVID -19 Coronavirus, Duke / 27.03.2020

MedicalResearch.com Interview with: Dr. Rupesh Agrawal, MD Associate Professor Senior Consultant Ophthalmologist Duke-NUS Medical School, Singapore MedicalResearch.com: What is the background for this study? Wasn't Dr Li Wenliang, the Chinese physician who first alerted his community of coronavirus an opthalmologist, with possible exposure to tears from this surgical work with glaucoma patients? Response: Since the start of the pandemic, there have been multiple reports which suggested the transmission of SARS-CoV-2 via ocular fluids. As ophthalmologists, we come into close contact with tears on a daily basis during our clinical examination. Furthermore, many equipment in the clinic like the Goldman tonometer come into direct contact with such ocular fluids, providing a channel for viral transmission. The evidence, as of date, were mainly anecdotal reports included in newspaper articles and media interviews. We wanted to know if the virus can truly be found in tears, so we decided to embark on this study. (more…)
Author Interviews, Mental Health Research, Pediatrics / 26.03.2020

MedicalResearch.com Interview with: Jillian Hardin, Ph.D. Developmental Psychophysiology Lab Florida Atlantic University MedicalResearch.com: What is the background for this study? Response: Most Kangaroo Care (KC) research examines the procedure’s positive physiological and psychological developmental effects on preterm infants as these infants are separated from their mothers before the end of gestation. However, the aim of our study was to determine whether kangaroo care parent-training and implementation with non-vulnerable, full-term infants provided developmental neurophysiological benefits.  (more…)
Author Interviews, Biomarkers, Diabetes, Diabetes Care, Johns Hopkins / 26.03.2020

MedicalResearch.com Interview with: Olive Tang, MD/PhD Student Johns Hopkins School of Medicine   Elizabeth Selvin, PhD, MPH Professor of Epidemiology & Medicine Director, Cardiovascular and Clinical Epidemiology Department of Epidemiology Welch Center for Prevention, Epidemiology and Clinical Research and the Johns Hopkins Bloomberg School of Public Health MedicalResearch.com: What is the background for this study? Response: The best approach to diabetes management in older adults is unclear. A new blood test called high-sensitivity troponin can detect damage to the heart, even in people without any signs or symptoms of heart disease. (more…)
Author Interviews, Melanoma, NYU / 25.03.2020

MedicalResearch.com Interview with: David Polsky, MD, PhD Professor of Dermatology and Pathology Alfred W. Kopf MD, Professor of Dermatologic Oncology Director, Pigmented Lesion Section The Ronald O. Perelman Department of Dermatology New York University Grossman School of Medicine Perlmutter Cancer Center Joan and Joel Smilow Research Center New York, NY 10016 MedicalResearch.com: What is the background for this study? Response: The background for the study was to determine the extent to which new treatments for metastatic melanoma were impacting melanoma mortality rates for the United States population. Multiple clinical trials have demonstrated that several new agents were highly effective at prolonging survival. These treatments belong to two different groups of medications: those targeting the biological pathway activated by mutation in the BRAF oncogene, which occurs in just under 50% of metastatic melanomas; and those targeting the immune system, called checkpoint inhibitors. These drugs prevent melanomas from suppressing the immune response to the tumors. Ten treatments were approved beginning in 2011, including six treatments between 2011 and 2014. We examined mortality rates between 1986 and 2016, prior to and after FDA approval of these agents. (more…)
Addiction, Author Interviews, Cannabis / 25.03.2020

MedicalResearch.com Interview with: Ryan J. McLaughlin, PhD Assistant Professor Department of Integrative Physiology & Neuroscience College of Veterinary Medicine Washington State University, Pullman, WA Ryan J. McLaughlin, PhD Assistant Professor Department of Integrative Physiology & Neuroscience College of Veterinary Medicine Washington State University, Pullman, WA MedicalResearch.com: What is the background for this study? Response: The evolving legal landscape concerning the use of cannabis has increased urgency to better understand its effects on the brain and behavior. Animal models are advantageous in this respect; however, researchers traditionally use forced injections of synthetic cannabinoids which fails to capture the complex effects of volitional cannabis consumption. In our study, we developed a novel model of cannabis self-administration using response-contingent delivery of vaporized cannabis extracts containing high concentrations of Δ9 tetrahydrocannabinol (THC) or cannabidiol (CBD). (more…)
Author Interviews, Genetic Research, Nature, Prostate Cancer, Vanderbilt / 24.03.2020

MedicalResearch.com Interview with: Jeffrey R. Smith, MD PhD Department of Medicine, Division of Genetic Medicine Vanderbilt-Ingram Cancer Center, and Vanderbilt Genetics Institute Vanderbilt University Medical Center Medical Research Service Tennessee Valley Healthcare System, Veterans Administration Nashville, TN MedicalResearch.com: What is the background for this study?   Response: Roughly 20% of men with prostate cancer have a family history of the disease, and 5% meet criteria for hereditary prostate cancer. Although prostate cancer has the greatest heritability of all common cancers (twice that of breast cancer), extensive heterogeneity of its inherited causes has presented a considerable obstacle for traditional pedigree-based genetic investigative approaches. Inherited causes across, as well as within families are diverse. This study introduced a new familial case-control study design that uses extent of family history as a proxy for genetic burden. It compared a large number of men with prostate cancer, each from a separate family with a strong history of the disease, to screened men with no personal or family history. The study comprehensively deconstructs how the 8q24 chromosomal region impacts risk of hereditary prostate cancer, introducing several new analytical approaches. The locus had been known to alter risk of prostate, breast, colon, ovarian, and numerous additional cancers. (more…)
Author Interviews, Erectile Dysfunction, JAMA, Karolinski Institute / 23.03.2020

MedicalResearch.com Interview with: Alexander Stridh, MSc Department of Clinical Neuroscience Karolinska Institute Solna, Sweden MedicalResearch.com: What is the background for this study? What are the main findings? Response: ​We wanted to investigate how large the effect size is in the placebo arm of clinical trials with PDE5Is for erectile dysfunction. The major findings in this study is that there is a placebo response in general in ED, though it is hard to tell if this is a genuine placebo effect rather than normal fluctuations in symptom severity among patients. Another interesting finding was that the placebo response seems largely more important when the cause of ED is mainly due to psychogenic factors, as in post traumatic stress disorder. Lastly there was an important finding that there was no difference between placebo and active drug with daily treatment of PDE5Is  for long term recovery of erectile function after prostate cancer treatment, a practice which is common in some places and seems to be questionable.  (more…)
Allergies, Asthma, Author Interviews, ENT / 23.03.2020

MedicalResearch.com Interview with: Joseph Han, MD FARS, FAAOA FAAAAI Medical Director for the Division of Allergy Eastern Virginia Medical School  MedicalResearch.com: What is the background for this study? Response: Chronic rhinosinusitis with nasal polyps (CRSwNP) is a type 2 inflammatory disease of the nasal passages and sinuses associated with a high symptom burden due to the chronic, relapsing nature of the disease. If you ask CRSwNP patients about the most important disease symptoms, they would say nasal congestion and decrease in smell. However, many CRSwNP patients would say that losing their sense of smell is particularly troublesome. This study was conducted to better understand the effect of dupilumab, which is approved in the U.S. for adults with uncontrolled CRSwNP, on sense of smell.   (more…)
Author Interviews, JAMA, Opiods, Pediatrics / 23.03.2020

MedicalResearch.com Interview with: Leah Nelson, MD MS Addiction Medicine Fellow University of New Mexico MedicalResearch.com: What is the background for this study? Response: With the progression of the opioid epidemic over the past decade, more women of reproductive age are seeking treatment for addiction. Many more pregnant women are prescribed methadone and buprenorphine, two opioid medications that prevent relapse and overdose. Maternal use of mediations for opioid use disorder is recommended because it lowers the risk to the fetus from uncontrolled drug use and also allows the mother to engage with prenatal care and social work. Subsequently, the number of infants born after prenatal exposure to opioids is increasing. Several previous studies have shown measurable differences in the cognitive scores of children after prenatal opioid exposure. However, much of the previous work was done on convenience samples (easy to recruit rather than rigorously matched for comparability) and the demographic characteristics of both mothers and children in the exposed and unexposed groups varied widely on important factors such as maternal education, socioeconomics, employment, tobacco use, and infant gender. Each of these factors has been demonstrated to impact early childhood development in the absence of opioid exposure. (more…)
Author Interviews, Orthopedics, Surgical Research / 23.03.2020

MedicalResearch.com Interview with: Pincus MD PhD Division of Orthopaedic Surgery, Department of Surgery University of Toronto Sunnybrook Health Sciences Centre, Division of Orthopaedic Surgery ICES, Toronto, Ontario, Canada MedicalResearch.com: What is the background for this study? Response: Controversy exists among arthroplasty surgeons and patients about the best surgical approach for total hip arthroplasty (THA) - one of the most common operations performed worldwide. In the last few years, the direct anterior approach has become increasingly popular compared to posterior and lateral approaches, partially as a result of advertising to patients.  We sought to determine whether a direct anterior surgical approach was associated with lower surgical complications compared to lateral and posterior approaches. (more…)
Author Interviews, HIV, NEJM / 20.03.2020

MedicalResearch.com Interview with: Susan Swindells MBBS Professor, Infectious Diseases Department of Internal Medicine University of Nebraska Medical Center Omaha, NE MedicalResearch.com: What is the background for this study? Response: The background for this study is the development of long-acting injectable formulations of two antiretroviral agents: cabotegravir and rilpivirine.  These were previously tested in a Phase 2 study, and the current study (called ATLAS) reports findings from Phase 3 in which HIV-infected patients on antiretroviral therapy were switched to monthly injections. The partner study, (FLAIR), is published in the same addition of the journal, and reports results from patients that were new to antiretroviral therapy, and took oral medications as a lead-in to achieve viral suppression before switching to similar monthly injections.  Both studies included randomization to continuing oral antiretroviral therapy. (more…)
Allergies, Author Interviews, Dermatology / 20.03.2020

MedicalResearch.com Interview with: Gil Yosipovitch, MD, Professor Miami Itch Center Lennar Medical Foundation South Miami Clinic in Coral Gables University of Miami Health System MedicalResearch.com: What is the background for this study? How does Dupilumab (Dupixent) differ from other medications for atopic dermatitis/eczema? Response: Atopic dermatitis (AD) is characterized by intense itch (pruritus) that is one of the most burdensome symptoms; therefore, rapid and sustained improvement in itch is an important marker of treatment benefit. Dupixent® (dupilumab) is approved in the U.S. for adults and adolescents with inadequately-controlled moderate-to-severe Atopic Dermatitis. Dupilumab remains the first and only biologic medicine for uncontrolled moderate-to-severe atopic dermatitis. Dupilumab is the first and only fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) proteins. Data from dupilumab clinical trials have shown that IL-4 and IL-13 are key drivers of the type 2 inflammation that plays a major role in atopic dermatitis, asthma and chronic rhinosinusitis with nasal polyps.  (more…)
Author Interviews, Cost of Health Care, Electronic Records / 20.03.2020

MedicalResearch.com Interview with: Rohit Bishnoi, M.D. Division of Hematology and Oncology Department of Medicine University of Florida Gainesville, FL MedicalResearch.com: What is the background for this study? Response: National Healthcare expenditure was $3.6 trillion in 2018 and 17.7% of Gross Domestic Product. Redundant laboratory testing is one part of this problem that is more pronounced in hospitalized patients as they are often seen by multiple physicians from the time of admission till discharge. This added burden on the US health care system leads to increased costs, decreased patient satisfaction, and unnecessary phlebotomy. It also leads to iatrogenic anemia over time and unnecessary transfusions. The Choosing Wisely initiative recommendation from the Society of Hospital Medicine, Society for the Advancement of Blood Management, and the Critical Care Societies Collaborative have recommended avoiding repetitive labs. As one of the physicians in the division of hospital medicine at the University of Florida (UF) Health Shands hospital, we encountered this problem frequently where a patient will get multiple HbA1c or lipid profiles or iron studies during the same hospital stay without any clear clinical indication. Most often these tests were ordered by different physicians seeing the same patient and not realizing that either the test has already been ordered or sometimes it is related to practice pattern of physicians. We often heard complaints about this from our nursing and laboratory staff and, most importantly by patients themselves. (more…)
Addiction, Author Interviews, JAMA, Mental Health Research / 20.03.2020

MedicalResearch.com Interview with: Jiajin Yuan, Ph.D Professor of Psychology Director, The Laboratory for Affect Cognition and Regulation, Faculty of Psychology, Southwest University, Chongqing, China MedicalResearch.com: What is the background for this study? Response: Impulsivity is a critical symptom of methamphetamine addiction, and this symptom plays an important role in compulsive, unresistable drug-seeking behavioral and is thus detrimental to the rehabilitation. Impulsivity in drug addiction also contributes to disruption of people's goal pursuit/goal maintenance, and aggressive/violent behaviors after drug use. Also, lack of suitable intervention for addiction-related impulsivity is known to be a risky factor for the drug reuse after successful rehabilitation. Thus, rehabilitaton targeted at impulsivity in methamphetamine addicts is important to comprehensive rehabilitation of the drug addiction and also to successful return to social life after rehabilitation (more…)
Author Interviews, Bristol Myers Squibb, Cancer Research, Pharmaceutical Companies / 19.03.2020

MedicalResearch.com Interview with: https://www.cgen.com/ Anat Cohen-Dayag, Ph.D. President and CEO Compugen MedicalResearch.com: What is the background for this announcement? Would you discuss Compugen’s underlying cancer hypothesis regarding the targeting of multiple checkpoint pathways to enhance tumor response? Response: Cancer immunotherapy has revolutionized the landscape for cancer treatments by providing new drug options leading to lasting benefits for patients. Yet, response rates vary greatly across different cancer indications, leaving a significant unmet medical need for many patients and a continuing challenge to discover new biological pathways that can serve for the development of new cancer immunotherapies for non-responsive and refractory patients. Using a computational approach which is designed to discover new biological pathways and drug targets, we identified PVRIG as a novel immune checkpoint and a newly discovered inhibitory pathway in the DNAM axis. Our hypothesis is that PVRIG and TIGIT (another inhibitory pathway discovered by us and others) are two parallel and complementary inhibitory pathways in the DNAM axis and that in certain tumor types and patient populations, there may be a need to block both PVRIG and TIGIT in order to enhance anti-tumor immune responses. Moreover, reported molecular intersections between the DNAM axis and the PD-1 pathway, the most prevalent pathway targeted by approved immunotherapies, suggest that there is a linkage between these three pathways. As such, our PVRIG inhibitor may work in synergy with PD-1 and TIGIT inhibitors, suggesting that various drug combinations may be required to address these three pathways based on their dominance in different cancer patients and cancer indications. With this recently announced Phase 1/2 triple combination study, we will be directly testing our hypothesis of an intersection between the three parallel immune checkpoint pathways – PVRIG, TIGIT and PD-1 – and that the simultaneous blockade of these pathways has the potential to synergistically enhance anti-tumor immune response and expand the reach of cancer immunotherapy to patients non-responsive or refractory to approved immunotherapies.  (more…)
Annals Internal Medicine, Author Interviews, Cannabis, Yale / 19.03.2020

MedicalResearch.com Interview with: Joshua D. Wallach, MS, PhD Assistant Professor of Epidemiology (Environmental Health Sciences) Yale School of Public Health New Haven, CT MedicalResearch.com: What is the background for this study? Response: Over the past few years, there has been growing interest in the potential health benefits of cannabidiol (CBD), a chemical compound in cannabis. Although only one CBD-derived prescription drug has been approved by the US Food and Drug Administration (FDA) for the treatment of epilepsy, I recently started seeing products containing CBD advertised and sold across the US (e.g. CBD in foods, beverages, dietary supplements, and cosmetics). I noticed that many of these products were being marketed with unproven claims to prevent, cure, and treat various conditions, and became interested in learning more about the research supporting the use of CBD, the potential for misleading claims, and impact that the CBD-industry may be having on research that is being generated and disseminated to the public. Research funding sources and other author conflicts of interests (e.g. consulting fees, honoraria, travel expenses) can influence the way that research is designed, conducted, and reported. Previous studies have consistently demonstrated associations between authors' conflicts of interest and proindustry conclusions in clinical research. Given the growing number of companies invested in CBD's commercial success, we decided to analyze the disclosed funding sources, conflicts of interest statements, author employment details, and CBD-related conclusions in a large sample of published articles on the characteristics, use, and therapeutic effects of cannabidiol. (more…)
Author Interviews, Dental Research, JAMA, Pain Research / 19.03.2020

MedicalResearch.com Interview with: Dr. Romesh P. Nalliah BDS, MHCM Associate Dean for Patient Services Clinical Professor Institute for Healthcare Policy & Innovation Michigan Institute for Data Science Director, Synergy Program MedicalResearch.com: What is the background for this study? Response: We designed and conducted this study because there is a paucity of knowledge related to opioid prescribing for acute dental pain. (more…)
Author Interviews, Gender Differences, Heart Disease, Karolinski Institute, Opiods, PNAS / 18.03.2020

MedicalResearch.com Interview with: Mikko Myrskylä PhD Executive Director, Max Planck Institute for Demographic Research Professorial Research Fellow, London School of Economics Professor of Social Statistics University of Helsinki MedicalResearch.com: What is the background for this study? Response: Life expectancy in the U.S. increased at a phenomenal pace throughout the twentieth century, by nearly two years per decade. After 2010, however, U.S. life expectancy growth stalled and has most recently been declining. A critical question for American health policy is how to return U.S. life expectancy to its pre-2010 growth rate. Researchers and policy makers have focused on rising drug-related deaths in their search for the explanations for the stalling and declining life expectancy. (more…)
Author Interviews, Cancer Research, Environmental Risks, Lung Cancer, Occupational Health / 18.03.2020

MedicalResearch.com Interview with: Theresa S. Emory MD Department of Pathology, Peninsula Pathology Associates Newport News, VA MedicalResearch.com: What is the background for this study? What are the main findings? Response: Cosmetic talc products can contain asbestos, which is the primary cause of malignant mesothelioma. We investigated 75 individuals with malignant mesothelioma, whose only known exposure to asbestos was repeated exposures to cosmetic talcum powder. 83% of the individuals were female and several occurred in barbers/cosmetologists. 16% occurred in individuals younger than 45 years old, and on average the subjects were 11 years younger than predicted, based on SEER data. The asbestos fibers in tissue samples that were examined in 11 cases were identical (anthophyllite and tremolite) to those identified in cosmetic talc. (more…)
Author Interviews, Dermatology, Pediatrics / 18.03.2020

MedicalResearch.com Interview with: Adawiyah Jamil, AdvMDerm Associate Professor at Department of Medicine University Kebangsaan Malaysia Medical Center Kuala Lumpur, Malaysia MedicalResearch.com: What is the background for this study? Response: We commonly observed poor dietary pattern and multiple food restrictions imposed on atopic dermatitis (AD) children by their parents in our daily clinical practice. Food allergy is often associated with AD, however excessive and medically unsubstantiated restriction may lead to various health issues. AD is a chronic skin disease, like any other chronic diseases it affects an individual’s general health. Growth and development are key measures of health in children. We embarked on this study as we were very worried of the consequences of medically unsupervised food restriction, especially those with severe disease.  We were concerned about how our atopic dermatitis children are eating and how to help them. (more…)
Author Interviews, Gastrointestinal Disease, JAMA, Orthopedics, Pediatrics / 17.03.2020

MedicalResearch.com Interview with: Yun-Han Wang, PhD Student Karolinska Institute MedicalResearch.com: What is the background for this study? Response: Proton pump inhibitor (PPI) use has been linked to increased risk of fracture in adults. Despite an increasing trend in prescription of PPIs in children, there is scarce evidence regarding this safety concern in pediatric patients. (more…)
Author Interviews, COVID -19 Coronavirus, Pharmaceutical Companies, Vaccine Studies / 17.03.2020

MedicalResearch.com Interview with: Nathalie Charland PhD Senior Director, Scientific and Medical Affairs Medicago  MedicalResearch.com: What is the background for this study? What are the main findings? Response: We started to work on solutions as soon as we were able to obtain the appropriate genetic information for the new COVID-19. Medicago is committed to advancing therapeutics against life-threatening diseases worldwide.  (more…)
Author Interviews, Opiods / 17.03.2020

MedicalResearch.com Interview with: Amir Pashmineh, MBS Geisinger Commonwealth School of Medicine MedicalResearch.com: What is the background for this study? Response: The opioid buprenorphine is a mu and nociceptin receptor partial agonist, and serves as an antagonist to kappa and delta receptors. These properties contribute to this medication being a first-line evidence-based agent in Opioid Use Disorder (OUD) treatment. There have been policy changes intended to increase buprenorphine (which goes by brand names Suboxone or Subutex) availability, but access remains below optimal levels. Relative to methadone, buprenorphine is more expensive. The “abstinence only” mentality of 12-step programs for addiction treatment continues to be influential. The objective of this study was to extend our pharmacoepidemiology knowledge regarding utilization and characterize the regional disparity in distribution in the U.S. over the last decade. Data was obtained from Drug Enforcement Administration’s Automated Reports and Consolidated Ordering System (ARCOS), a comprehensive drug reporting system of controlled substances from their point of manufacturing to point of sale and distribution. (more…)
Author Interviews, COVID -19 Coronavirus / 16.03.2020

MedicalResearch.com Interview with: Sibaji Sarkar, Ph.D. Adj. Professor Quincy College, Quincy, Boston MA MBC College, Wellesley MA RC College, Boston, MA  MedicalResearch.com: What is the background for this study? Response: COVID-19 infection is spreading and nothing is out there now to stop it. Hopefully, vaccines will be made and will be useful but that may take months if not a year. Researchers are also testing the use of other anti-viral drugs. COVID-19 uses (angiotensin converting enzyme receptor 2) ACE2 on capillary membranes of lungs to attach and then enter by endocytosis. ACE and ACE2 are two different types of receptors. ACE inhibitors are regularly in use as blood pressure lowering drugs. Unfortunately, ACE inhibitors have very les affinity for ACE2. Theoretically, if COVID-19 and any ACE2 inhibitor share similar binding site on ACE2 or at least bind in close proximity, assuming the virus is a big particle, it should fully or partially block viral entry. That will reduce or delay disease progression. (more…)
Author Interviews, JAMA, Pediatrics, Weight Research / 16.03.2020

MedicalResearch.com Interview with: Ashlesha Datar, PhD Senior Economist Director of Program on Children & Families USC Dornsife Center for Economic and Social Research (CESR) University of Southern California  MedicalResearch.com: What is the background for this study? Response: Prior research, including our own work, has suggested that there might be some kind of social contagion or social transmission in obesity. So we wanted to explore that avenue further. In the present study, we showed teens in military families a set of human body figures with varying body sizes and asked them to choose the figure that best captured their ideal body size. (more…)
Author Interviews, COVID -19 Coronavirus, Vaccine Studies / 13.03.2020

MedicalResearch.com Interview with: Cynthia Liu,  Ph.D. Manager, Scientific Information CAS, a division of the American Chemical Society Columbus, OH 43210 MedicalResearch.com: What is the background for this study? Response: The outbreak of COVID-19 caused by the new virus SARS-CoV-2 has overwhelmed the health systems in many countries and been declared by WHO as a pandemic which will continue to affect global public health and world economy. This threat calls for an intensified effort in the development of therapeutic agents and vaccines. CAS is a not-for-profit division of the American Chemical Society that specializes in scientific information solutions. Our team includes hundreds of scientists that build a global data collection of curated scientific content from both journal articles and patent applications as well as chemical and biological substance collections. With this report, our team hopes to support the efforts of R&D organizations seeking to address this crisis by providing an up-to-date overview of recent relevant publications and insight into potential therapeutic agents, including both small molecules and biologics. (more…)